does blue cross blue shield cover glp-1 drugs Could Raise Employer Health Premiums IBX members face GLP-1 drug
Description
This trend has been observed particularly in aging populations, including Korea, where one in four people with diabetes mellitus is affected by DKD, and the prevalence of ESKD continues to rise in older adults [3]
Several pharmaceutical companies are well-positioned to benefit from the GLP-1 market expansion
Combined with the increased lipolysis (fat breakdown) and thermogenesis (fat burning), the net effect on body composition is more favorable than what either GLP-1 or GIP agonism can produce alone
About 40% of adults in the U.S
